Gadolinium released from MR contrast agents is deposited in brain tumors: in situ demonstration using scanning electron microscopy with energy dispersive X-ray spectroscopy

References

• Spencer A, Wilson S, Harpur E. Gadolinium chloride toxicity in the mouse. Hum Exp Toxicol 1998;17:633–7.
   PubMed Web of Science ®Google Scholar
• Spencer AJ, Wilson SA, Batchelor J, Reid A, Rees J, Harpur E. Gadolinium chloride toxicity in the rat. Toxicol Pathol 1997;25:245–55.
   PubMed Web of Science ®Google Scholar
• Behra-Miellet J, Gressier B, Brunet C, Dine T, Luyckx M, Cazin M, . Free gadolinium and gadodiamide, a gadolinium chelate used in magnetic resonance imaging: evaluation of their in vitro effects on human neutrophil viability. Methods Find Exp Clin Pharmacol 1996;18:437–42.
   Google Scholar
• Grobner T. Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21: 1104–8.
   PubMed Web of Science ®Google Scholar
• Thomsen HS. Is NSF only the tip of the “gadolinium toxicity” iceberg? J Magn Reson Imaging 2008;28:284–6.
   PubMed Web of Science ®Google Scholar
• Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, . Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17:2359–62.
   PubMed Web of Science ®Google Scholar
• Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 2007;80:73–6.
   PubMedGoogle Scholar
• Abraham JL, Edward M. Free gadolinium is a likely trigger of nephrogenic systemic fibrosis. Am J Roentgenol 2009;193: W354; author reply W355.
   Google Scholar
• Edward M, Quinn JA, Mukherjee S, Jensen MB, Jardine AG, Mark PB, . Gadodiamide contrast agent ‘activates’ fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 2008;214:584–93.
   PubMedGoogle Scholar
• Vakil V, Sung JJ, Piecychna M, Crawford JR, Kuo P, Abu-Alfa AK, . Gadolinium-containing magnetic resonance image contrast agent promotes fibrocyte differentiation. J Magn Reson Imaging 2009;30:1284–8.
   Google Scholar
• Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998;5:491–502.
   PubMed Web of Science ®Google Scholar
• Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008;43:141–4.
   PubMed Web of Science ®Google Scholar
• Kalb RE, Helm TN, Sperry H, Thakral C, Abraham JL, Kanal E. Gadolinium-induced nephrogenic systemic fibrosis in a patient with an acute and transient kidney injury. Br J Dermatol 2008;158:607–10.
   Google Scholar
• Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 2007;158:273–80.
   Google Scholar
• Thakral C, Abraham JL. Automated scanning electron microscopy and x-ray microanalysis for in situ quantification of Gadolinium deposits in skin. J Electron Microsc (Tokyo) 2007;56:181–7.
   Google Scholar
• Thakral C, Alhariri J, Abraham JL. Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. Contrast Media Mol Imaging 2007; 2:199–205.
   PubMed Web of Science ®Google Scholar
• Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 2007;56:27–30.
   PubMed Web of Science ®Google Scholar
• George SJ, Webb SM, Abraham JL, Cramer SP. Synchrotron X-ray analyses demonstrate phosphate-bound gadolinium in skin in nephrogenic systemic fibrosis. Br J Dermatol 2010 Jun 19 [E-pub ahead of print].
   Google Scholar
• Essig M, Weber MA, von Tengg-Kobligk H, Knopp MV, Yuh WT, Giesel FL. Contrast-enhanced magnetic resonance imaging of central nervous system tumors: agents, mechanisms, and applications. Top Magn Reson Imaging 2006;17:89–106.
   PubMedGoogle Scholar
• SAS Institute. JMP. 1989–2007; Version 7.
   Google Scholar
• Alves FC, Donato P, Sherry AD, Zaheer A, Zhang S, Lubag AJ, . Silencing of phosphonate-gadolinium magnetic resonance imaging contrast by hydroxyapatite binding. Invest Radiol 2003;38:750–60.
   Google Scholar
• Idee JM, Port M, Raynal I, Schaefer M, Le Greneur S, Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 2006;20: 563–76.
   PubMed Web of Science ®Google Scholar
• Abraham JL, Chandra S, Thakral C, Abraham JM. SIMS imaging of gadolinium isotopes in tissue from nephrogenic systemic fibrosis patients: release of free Gd from magnetic resonance imaging contrast agents. App Surf Sci 2008;255: 1181–4.
   Google Scholar
• Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F, . Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 2008; 18:2164–73.
   PubMed Web of Science ®Google Scholar
• White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 2006;41:272–8.
   PubMed Web of Science ®Google Scholar
• Maramattom BV, Manno EM, Wijdicks EF, Lindell EP. Gadolinium encephalopathy in a patient with renal failure. Neurology 2005;64:1276–8.
   PubMed Web of Science ®Google Scholar
• Ray DE, Holton JL, Nolan CC, Cavanagh JB, Harpur ES. Neurotoxic potential of gadodiamide after injection into the lateral cerebral ventricle of rats. Am J Neuroradiol 1998;19:1455–62.
   PubMed Web of Science ®Google Scholar
• Ray DE, Cavanagh JB, Nolan CC, Williams SC. Neurotoxic effects of gadopentetate dimeglumine: behavioral disturbance and morphology after intracerebroventricular injection in rats. Am J Neuroradiol 1996;17:365–73.
   PubMed Web of Science ®Google Scholar
• Li L, Gao FQ, Zhang B, Luo BN, Yang ZY, Zhao J. Overdosage of intrathecal gadolinium and neurological response. Clin Radiol 2008;63:1063–8.
   Google Scholar
• Roman-Goldstein SM, Barnett PA, McCormick CI, Ball MJ, Ramsey F, Neuwelt EA. Effects of gadopentetate dimeglumine administration after osmotic blood-brain barrier disruption: toxicity and MR imaging findings. Am J Neuroradiol 1991;12:885–90.
   Google Scholar
• Mizgerd JP, Molina RM, Stearns RC, Brain JD, Warner AE. Gadolinium induces macrophage apoptosis. J Leukoc Biol 1996;59:189–95.
   PubMed Web of Science ®Google Scholar
• Strande JL, Routhu KV, Hsu A, Nicolosi AC, Baker JE. Gadolinium decreases inflammation related to myocardial ischemia and reperfusion injury. J Inflamm (Lond) 2009;6:34.
   Google Scholar